An interventional study of Pectin and Cocoa Powder in Nonalcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease (NAFLD) and MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, sponsored by University of Nottingham. Recruiting at 3 sites in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by University of Nottingham · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom — 17 open to participants now, 27 under way, 9 of them phase 3. Non-alcoholic Fatty Liver Disease · United Kingdom.
Among the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, this one is the 69th largest by planned enrollment of the 101 interventional ones that give a count, is one of 6 that started in 2025, is one of 30 with no phase, reaches primary completion later than 9 of the 26 other live ones, and was the 120th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →17 of the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United Kingdom, United States, Puerto Rico
Ages 18–75
Eli Lilly and Company · Sites in United Kingdom, United States, Argentina and 31 more countries
Ages 18+
University of Oxford · Sites in United Kingdom
Ages 18+ · Women only
Akero Therapeutics, Inc · Sites in United Kingdom, United States, Argentina and 20 more countries
Ages 18–80
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 18+ · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 41 · Phase 3 19 · Phase 4 4
First in 2008; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 104 across the 101 interventional studies, 153 across the 21 observational. Of the 86 that completed or were terminated, 44 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 122 have an industry lead sponsor. The 10 most frequent:
University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.
University of Nottingham has 6 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
6 of the studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07093346University of NottinghamThe Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | 2027-03-31 |
| NCT04666402Manchester University NHS Foundation TrustIntegrated Diagnostics for Early Diagnosis of Liver Disease | 2027-03-31 |
| NCT06920316St. George's Hospital, LondonDigital Diet and Exercise Intervention to Reduce Liver Fibrosis in Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) | 2027-05 |
| NCT04141592Queen Mary University of LondonInvestigating Pathological Mechanisms in Non-alcoholic Fatty Liver Disease | 2027-07-31 |
| NCT06836609Regeneron PharmaceuticalsA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) | 2027-08-17 |
Add all 6 to your calendar (.ics) → With an account.
Among the 122 studies in Non-alcoholic Fatty Liver Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce systemic inflammation and improve gut microbiota composition in adults recently diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The main question it aims to answer is:
-How does dietary Low-methoxy (LM) pectin supplementation affect systematic inflammation pathways such as those mediated by gut microbiota composition and what are the impacts on general metabolic indicators in individuals with MASLD?
Researchers will compare a group taking 15g of LM-pectin with 10g of cocoa powder to a placebo group receiving 10g of placebo with 10g of cocoa powder to see if LM-pectin has measurable effects on inflammation and gut microbiota.
Participants will:
Primary Objective:
This research aims to study the effects of daily ingestion of LM pectin on inflammation pathways by measuring the blood inflammatory markers associated with physiological processes (TNFα, IL-6, IL-10, IFNᵞ, C - reactive protein, Zonulin (Haptoglobulin), IL-1β).
Secondary Objectives:
Inclusion Criteria:
Inclusion criteria for the main study:
Inclusion criteria for healthy participants who will have MRI scans:
Exclusion Criteria:
Exclusion criteria for the main study:
Exclusion criteria for healthy volunteers MRI scans and patients optional MRI scans:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
15g/day of pectin with 10g/day of cocoa powder added as flavour will be provided to participants for 6 weeks.
Dietary Supplement: Pectin
10g/day of cocoa powder will be provided to participants for 6 weeks.
Other: Cocoa Powder
To validate MRI scans as a tool to assess intestinal wall thickness to indicate gut permeability on MASLD patients, the investigators will scan 15 healthy volunteers twice, at baseline and after 6 weeks, and then compare their results with MASLD participant results at baseline and after 6 weeks.
Diagnostic Test: Magnetic Resonance Imaging with Contrast
15g of pectin with 10g of cocoa powder added as flavour were randomly allocated to eligible participants.
10g of cocoa powder served as the control/ placebo to compare the effects observed with pectin.
To validate MRI scans as a tool to assess intestinal wall thickness to indicate gut permeability on MASLD patients, the investigators will scan 15 healthy volunteers twice, at baseline and after 6 weeks, and then compare their results with MASLD participant results at baseline and after 6 weeks.
Also known as: MRI
Quantification of blood markers contributing to systemic inflammation pathway (TNFα (pg/mL), IL-6 (pg/mL), IL-10 (pg/mL), IFNᵞ (pg/mL), C-Reactive Protein (pg/mL), Zonulin (Haptoglobulin)(pg/m), IL-1β(pg/mL)).
Change in circulating markers of inflammation measured by ELISAs in serum samples collected pre and post the 6-weeks intervention period.
Time frame: 6 weeks
Change in BMI (kg/m²)
Changes in BMI pre and post the 6-weeks intervention period.
Time frame: 6 weeks
Assessment of changes in general metabolic indicators, such as fasting blood glucose and other blood-based markers relevant to MASLD (e.g., CK18-M30, CK18-M65, PROC3, Enhanced Liver Fibrosis (ELF), NIS2+™, YKL-40, microRNA miR-34a-5p)
Changes in general metabolic indicators, such as fasting blood glucose and other blood-based markers relevant to MASLD (e.g., CK18-M30, CK18-M65, PROC3, Enhanced Liver Fibrosis (ELF), NIS2+™, YKL-40, microRNA miR-34a-5p) pre and post the 6-weeks intervention period.
Time frame: 6 weeks
Assessment of changes in liver-associated enzymes such as Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), gamma-glutamyl transferase (GGT), Alkaline Phosphatase (ALP)), bilirubin levels, lipid profiles, and platelet counts.
Changes in liver-associated enzymes such as Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), gamma-glutamyl transferase (GGT), Alkaline Phosphatase (ALP)), bilirubin levels, lipid profiles, and platelet counts pre and post the 6-weeks intervention period.
Time frame: 6 weeks
Change in Liver Stiffness via Transient Elastography
CAP and liver stiffness (in kPa) measured using transient elastography.
Time frame: 6 weeks
Change in Liver Fat Fraction Assessed by Dixon MRI Sequence.
Fat fraction (%) in liver and abdominal organs assessed using Dixon MRI before and after the 6-week intervention.
Time frame: 6 weeks
Change in Intestinal Permeability Measured by T2* MRI.
T2\* values in gut wall tissue will be compared before and after the intervention as a proxy for gut permeability.
Time frame: 6 weeks
Investigation the presence of gene variants such as MUC2, encoding Mucin protein, that are associated with gut permeability.
Genetic variants such as MUC2 will be determined where consent for genetic analysis is given.
Time frame: 6 weeks
Change in Systolic Blood Pressure (mmHg)
Change in Systolic Blood Pressure (mmHg) before and after the 6-week intervention.
Time frame: 6 weeks
Change in Diastolic Blood Pressure (mmHg)
Change in Diastolic Blood Pressure (mmHg) before and after the 6-week intervention.
Time frame: 6 weeks
Change in Heart Rate (beats/minute)
Change in Heart Rate (beats/minute) before and after the 6-week intervention.
Time frame: 6 weeks
Change in Waist-to-Hip Ratio
Change in Waist-to-Hip Ratio before and after the 6-week intervention.
Time frame: 6 weeks
Plan to share: Undecided
Started Jun 2025 (actual). Primary completion is estimated for Mar 2027, 21 months after the start.
Of 356 non-industry interventional studies with no phase under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 21 months is below that.
Counting every sponsor, half of 384 studies reached it within 25 months; a quarter within 12 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pectins
Non-alcoholic Fatty Liver Disease →